| Dr Fernando A Gutierrez, MD | |
|
133 E Frederick St, Lancaster, PA 17602-2222 | |
| (717) 394-9821 | |
| (717) 394-0175 |
| Full Name | Dr Fernando A Gutierrez |
|---|---|
| Gender | Male |
| Speciality | Anesthesiology |
| Experience | 30 Years |
| Location | 133 E Frederick St, Lancaster, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1396735494 | NPI | - | NPPES |
| 0019161670003 | Medicaid | PA |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207L00000X | Anesthesiology | MD-418790 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Lancaster General Hospital | Lancaster, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Lancaster General Hospital | 1254240039 | 408 |
News Archive
Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient's own cells, but this takes several months.
Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.
vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
› Verified 4 days ago
| Entity Name | Anesthesia Associates Of Lancaster, Ltd. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780675835 PECOS PAC ID: 4587559224 Enrollment ID: O20040220000219 |
News Archive
Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient's own cells, but this takes several months.
Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.
vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
› Verified 4 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1154331775 PECOS PAC ID: 1254240039 Enrollment ID: O20040414000520 |
News Archive
Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient's own cells, but this takes several months.
Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.
vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
› Verified 4 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1750399507 PECOS PAC ID: 1254240039 Enrollment ID: O20050606000065 |
News Archive
Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient's own cells, but this takes several months.
Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.
vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
› Verified 4 days ago
| Entity Name | Lancaster General Hospital |
|---|---|
| Entity Type | Part B Supplier - Hospital Department(s) |
| Entity Identifiers | NPI Number: 1730323759 PECOS PAC ID: 1254240039 Enrollment ID: O20090710000234 |
News Archive
Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient's own cells, but this takes several months.
Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.
vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Fernando A Gutierrez, MD 133 E Frederick St, Lancaster, PA 17602-2222 Ph: (717) 394-9821 | Dr Fernando A Gutierrez, MD 133 E Frederick St, Lancaster, PA 17602-2222 Ph: (717) 394-9821 |
News Archive
Cytokine storms created by COVID-19 are causing major organ destruction and death, and for the first time in the United States, when patients begin to show signs of trouble, physicians are replacing the usual filter in a kidney dialysis machine with a filter known to trap these tiny proteins, with the goal of avoiding the devastation.
Scientists from USA have developed a method to produce a ready made supply of blood vessels for use in heart bypass surgery. A study on baboons and dogs reported in journal Science Translational Medicine suggests vessels could be stored for up to a year and used by any patient. These vessels have been grown earlier from a patient's own cells, but this takes several months.
Scientists from Chimerix, Inc. today presented in vitro data demonstrating that the company's lipid-conjugated drugs, CMX001 and CMX157, are not substrates for the human Organic Anion Transporters (hOATs) and thus have significantly reduced potential to cause nephrotoxicity via this mechanism.
vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.
AdvanDx today announced that it has received FDA 510(k) clearance for a fast, 90 minutes protocol for its S. aureus PNA FISH® and S. aureus/CNS PNA FISH® tests. The faster protocol reduces the PNA FISH turn-around time from the original 2.5 hours to 90 minutes by reducing PNA probe hybridization from 90 minutes to 30 minutes.
› Verified 4 days ago
Dr. Ashima Arora Vaswani, M.D. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 College Ave, Lancaster, PA 17603 Phone: 717-358-7349 Fax: 717-291-6734 | |
Casey Joseph Prather, D.O. Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 250 College Ave Fl 1, Lancaster, PA 17603 Phone: 717-358-7349 Fax: 717-291-6734 | |
Dr. Salvatore J Astarita, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Jon B Turula, MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Margaret A Motl, MD Anesthesiology Medicare: Medicare Enrolled Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Robert B Falk Jr., MD Anesthesiology Medicare: Not Enrolled in Medicare Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 | |
Dr. Kevin F Slenker, MD Anesthesiology Medicare: Accepting Medicare Assignments Practice Location: 133 E Frederick St, Lancaster, PA 17602 Phone: 717-394-9821 Fax: 717-394-0175 |